听力损失治疗市场－全球产业规模、份额、趋势、机会及预测（按产品、疾病类型、最终用户、地区和竞争格局划分，2021-2031年）

全球听力损失治疗市场预计将从 2025 年的 185.6 亿美元成长到 2031 年的 264.9 亿美元，复合年增长率为 6.11%。

该市场涵盖人工电子耳、助听器等医疗设备的供应，以及旨在控制和缓解听力损失的药物干预措施。推动这一增长的关键因素包括全球人口老化（老年人患老龄化性听力损失的风险更高）以及不同人群中噪音性耳聋发病率的上升。据欧洲助听器製造商协会 (EHEIA) 称，其成员公司报告称，2025 年全球助听器总销量将达到 2,269 万台，高于 2024 年的水平。这一趋势证实了市场对听力管理解决方案的持续需求，而全球健康促进计划和不断提高的诊断率也为此提供了支持。

儘管市场呈现成长态势，但新兴经济体中设备高成本、健保覆盖不足等问题仍构成重大障碍。这些经济限制往往阻碍患者获得基本医疗保健服务，并妨碍现代治疗方法的广泛应用，尤其是在自付医疗费用对普通消费者而言负担沉重的地区。因此，儘管听力损失治疗的需求不断增长，但经济障碍阻碍了市场的全面渗透，并限制了经济困难人群获得先进听力保健服务的机会。

市场驱动因素

人工电子耳和骨传导助听系统的技术进步正从根本上重塑市场格局，提升设备的有效性和使用者连结性。製造商正积极将人工智慧和无线功能融入助听解决方案，加速了追求更高生活品质人群的接受度。这一趋势得到了强劲的行业表现支撑，例如科利耳有限公司（Cochlear Limited）发布的2024年年度报告（2024年8月），报告显示其收入增长15%至22.58亿美元，主要得益于人工电子耳销量增长9%。此外，更广泛的医疗设备市场也保持强劲势头，索诺瓦（Sonova）2024年的总收入达到36.269亿瑞士法郎，显示全球对先进助听器和听力保健的需求持续旺盛。

耳科领域新型药物疗法和再生医学的出现，标誌着治疗方式从症状治疗到潜在根治性介入的变革性转变。基因疗法的最新突破为遗传性感觉神经性听力损失患者带来了新的希望，并引起了医学界的广泛关注。根据礼来公司2024年1月发布的关于AK-OTOF-101试验的新闻稿，一名11岁受试者在接受基因治疗30天内听力得到恢復，听阈值从重度听力损失改善至65-20 dB HL范围。生物介入领域的这些进展预示着，未来药物治疗将与传统的器械治疗策略相辅相成，并显着扩大可治疗的听力障碍范围。

市场挑战

助听器价格高昂，加上保险覆盖范围有限，造成了巨大的经济障碍，严重阻碍了全球听力损失治疗市场的成长。在许多新兴经济体，由于缺乏完善的保险体系，患者不得不自费承担全部听力治疗费用，使得人工电子耳和高级助听器等必要的医疗设备对普通消费者而言难以负担。这种经济差距限制了市场准入，只有一小部分富裕人群能够获得这些设备，从而阻碍了助听器的普及，也使该行业无法充分利用人口密集地区听力障碍患者日益增多的趋势。

此外，这些经济限制因素导致疾病盛行率与实际治疗率之间持续存在脱节。依赖自费支出限制了患者的就医途径，使得大量目标人口无法得到治疗，并阻碍了市场将潜在需求转化为实际销售的能力。根据欧洲助听器製造商协会（EHIMA）的数据，预计到2025年，德国助听器的普及率仅47%（针对自述听力损失者）。这项数据反映了已开发市场目前的现状：经济和就医障碍导致很大一部分患者无法获得服务，而这一趋势在资金体系薄弱的发展中地区无疑更为严峻。

市场趋势

蓝牙低功耗音讯和Auracast广播功能的融合正在革新全球听力损失市场的连接方式。这项技术超越了传统的无线音讯传输，实现了标准化的高品质音讯传输，同时显着降低了功耗，消除了用户对连接设备电池续航时间的担忧。此外，Auracast还支援在机场、剧院和会议中心等公共场所实现无缝的一对多广播，使用户无需借助任何辅助设备即可直接接收场馆的音讯串流。这项创新正在推动市场实现实际成长。根据GN Store Nord于2025年2月发布的2024年度报告，其听力事业部预计将实现10%的有机收入增长，这主要得益于ReSound Nexia产品系列的成功上市，该系列是首款搭载原生Auracast技术的助听器。

同时，非处方（OTC）助听器类别的商业性扩张正在重塑产业的经销和普及模式。这一趋势旨在透过允许受监管的医疗设备无需处方笺处方即可透过零售和线上管道直接销售给消费者，从而实现听力保健的民主化。虽然此举旨在降低轻度至中度听力损失患者的成本和心理负担，但由于使用者仍然重视专业的验配和支持，因此消费者的接受度仍然较低。这种对临床督导的偏好也体现在使用统计数据中。美国听力损失协会在其《听力生活》杂誌上发表的一项2024年春季调查显示，仅有2%的受访者使用非处方助听器，而80%的受访者依赖处方笺助听器。这表明，儘管非处方助听器已获得监管许可，但该领域仍处于起步阶段。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球听力损失治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（医疗设备、药品（全身性类固醇、抗病毒药物、血管扩张剂等））
  • 依疾病类型（传导性听力损失、感音性听障、混合性听力损失（传导性和感音神经性听力损失））
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美听力损失治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲听力损失治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区听力损失治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲听力损失治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲听力损失治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球听力损失治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Otonomy Inc.
• Acousia Therapeutics GmbH
• Sensorion SA
• Pipeline Therapeutics
• Frequency Therapeutics
• Astellas Pharma Inc.
• Audina Hearing Instruments Inc.
• WS Audiology A/S
• Audifon GmbH & Co. KG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hearing Loss Disease Treatment Market is projected to expand from USD 18.56 Billion in 2025 to USD 26.49 Billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 6.11%. This market includes the supply of medical devices, such as cochlear implants and hearing aids, as well as pharmaceutical interventions aimed at managing or mitigating auditory deficits. Key drivers of this growth include an aging global population prone to age-related hearing decline and an increasing incidence of noise-induced auditory impairment across various demographics. According to the European Hearing Instrument Manufacturers Association, member companies reported total worldwide sales of 22.69 million hearing aids for the 2024 operating year in 2025. This trend underscores the persistent demand for auditory management solutions, supported by global health initiatives and improved diagnosis rates.

Despite this growth trajectory, the market encounters significant hurdles related to the high cost of devices and inadequate reimbursement coverage in emerging economies. These financial constraints frequently limit patient access to essential care and hinder the widespread adoption of modern treatment modalities, especially in regions where out-of-pocket healthcare costs represent a substantial burden for the average consumer. Consequently, while the demand for hearing loss treatments is rising, economic barriers prevent full market penetration and restrict access to advanced auditory healthcare for populations in financially constrained environments.

Market Driver

Technological advancements in cochlear implants and bone-anchored hearing systems are fundamentally reshaping the market by improving device efficacy and user connectivity. Manufacturers are increasingly incorporating artificial intelligence and wireless capabilities into auditory solutions, accelerating their adoption among individuals seeking an enhanced quality of life. This trend is supported by robust sector performance; for instance, Cochlear Limited reported in its 'Annual Report 2024' (August 2024) that sales revenue grew by 15% to $2,258 million, driven by a 9% increase in cochlear implant units. Furthermore, the broader device market remains strong, with Sonova generating total sales of CHF 3,626.9 million in 2024, highlighting sustained global demand for advanced hearing instruments and audiological care.

The emergence of novel pharmacological therapies and regenerative medicine for otology marks a transformative shift from symptomatic management to potential curative interventions. Recent breakthroughs in gene-based treatments offer new hope for patients with genetic sensorineural deficits, garnering significant attention from the medical community. According to a January 2024 press release by Eli Lilly and Company regarding the AK-OTOF-101 trial, an 11-year-old participant achieved hearing restoration within 30 days of gene therapy administration, with thresholds improving from profound loss to a range of 65 to 20 dB HL. This progress in biological interventions suggests a future where pharmaceutical solutions complement traditional device-based strategies, significantly expanding the scope of treatable auditory conditions.

Market Challenge

The substantial financial barrier posed by the high cost of hearing devices, combined with limited reimbursement coverage, significantly impedes the growth of the Global Hearing Loss Disease Treatment Market. In many emerging economies, the lack of comprehensive insurance schemes compels patients to bear the full financial burden of auditory care, making essential medical devices like cochlear implants and advanced hearing aids unaffordable for the average consumer. This economic disconnect effectively restricts market reach to a small, affluent segment of the population, thereby stifling mass adoption and preventing the industry from capitalizing on the rising prevalence of hearing impairment in these densely populated regions.

Furthermore, these financial constraints create a persistent gap between disease prevalence and actual treatment uptake. The reliance on out-of-pocket expenditure restricts patient access, leaving a large portion of the target demographic untreated and challenging the market's ability to convert potential demand into actual sales volume. According to the European Hearing Instrument Manufacturers Association (EHIMA), in 2025, the adoption rate of hearing aids in Germany was reported to be only 47% among individuals with self-reported hearing loss. This statistic illustrates that even in developed markets, economic and access barriers leave the majority of the patient population unserved, a trend that is undoubtedly more severe in developing regions with weaker financial support systems.

Market Trends

The integration of Bluetooth LE Audio and Auracast broadcasting capabilities is revolutionizing the connectivity landscape of the Global Hearing Loss Disease Treatment Market. This technology surpasses traditional wireless streaming by enabling standardized, high-quality audio transmission with significantly lower power consumption, addressing critical concerns regarding battery life in connected devices. Moreover, Auracast facilitates seamless, one-to-many broadcasting in public spaces like airports, theaters, and conference centers, allowing users to tune directly into venue audio streams without proprietary assistive hardware. This innovation is driving tangible market gains; according to GN Store Nord's 'Annual Report 2024' from February 2025, the Hearing division achieved 10% organic revenue growth, largely fueled by the successful launch of the ReSound Nexia product family, the first hearing aid to feature native Auracast technology.

Simultaneously, the commercial expansion of Over-the-Counter (OTC) hearing aid categories is reshaping distribution and accessibility models within the industry. This trend aims to democratize auditory care by permitting the sale of regulated medical devices directly to consumers through retail and online channels, bypassing the need for a professional prescription. While designed to lower costs and reduce stigma for those with mild-to-moderate impairment, consumer uptake remains cautious as users continue to value professional fitting and support. This preference for clinical oversight is reflected in usage statistics; a Spring 2024 survey by the Hearing Loss Association of America in 'Hearing Life' magazine revealed that only 2% of respondents utilized over-the-counter hearing aids, whereas 80% relied on prescription devices, indicating the segment is still in a nascent stage despite regulatory availability.

Key Market Players

• Otonomy Inc.
• Acousia Therapeutics GmbH
• Sensorion SA
• Pipeline Therapeutics
• Frequency Therapeutics
• Astellas Pharma Inc.
• Audina Hearing Instruments Inc.
• WS Audiology A/S
• Audifon GmbH & Co. KG

Report Scope

In this report, the Global Hearing Loss Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hearing Loss Disease Treatment Market, By Product

• Devices
• Drugs (Systemic Steroids, Antiviral Medication, Vasodilators, Others)

Hearing Loss Disease Treatment Market, By Disease Type

• Conductive Hearing Loss
• Sensorineural Hearing Loss
• Mixed (Conductive Sensorineural)

Hearing Loss Disease Treatment Market, By End user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Hearing Loss Disease Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hearing Loss Disease Treatment Market.

Available Customizations:

Global Hearing Loss Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hearing Loss Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Devices, Drugs (Systemic Steroids, Antiviral Medication, Vasodilators, Others))
  • 5.2.2. By Disease Type (Conductive Hearing Loss, Sensorineural Hearing Loss, Mixed (Conductive Sensorineural))
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Hearing Loss Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease Type
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hearing Loss Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Hearing Loss Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Hearing Loss Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End user

7. Europe Hearing Loss Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease Type
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hearing Loss Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End user
  • 7.3.2. France Hearing Loss Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Hearing Loss Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Hearing Loss Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Hearing Loss Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End user

8. Asia Pacific Hearing Loss Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease Type
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hearing Loss Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End user
  • 8.3.2. India Hearing Loss Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Hearing Loss Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Hearing Loss Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Hearing Loss Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End user

9. Middle East & Africa Hearing Loss Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease Type
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hearing Loss Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Hearing Loss Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Hearing Loss Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End user

10. South America Hearing Loss Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease Type
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hearing Loss Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Hearing Loss Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Hearing Loss Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hearing Loss Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otonomy Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Acousia Therapeutics GmbH
• 15.3. Sensorion SA
• 15.4. Pipeline Therapeutics
• 15.5. Frequency Therapeutics
• 15.6. Astellas Pharma Inc.
• 15.7. Audina Hearing Instruments Inc.
• 15.8. WS Audiology A/S
• 15.9. Audifon GmbH & Co. KG

16. Strategic Recommendations

17. About Us & Disclaimer